MX2021014523A - Metodos para tratar colangiocarcinoma. - Google Patents
Metodos para tratar colangiocarcinoma.Info
- Publication number
- MX2021014523A MX2021014523A MX2021014523A MX2021014523A MX2021014523A MX 2021014523 A MX2021014523 A MX 2021014523A MX 2021014523 A MX2021014523 A MX 2021014523A MX 2021014523 A MX2021014523 A MX 2021014523A MX 2021014523 A MX2021014523 A MX 2021014523A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- cholangiocarcinoma
- patient
- treating cholangiocarcinoma
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporciona en la presente métodos para tratar colangiocarcinoma avanzado metastásico en un paciente al administrar al paciente infigratinib o una sal farmacéuticamente aceptable del mismo, en donde el paciente tiene progresión del colangiocarcinoma después de la administración previa de otra terapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962853431P | 2019-05-28 | 2019-05-28 | |
PCT/US2020/034881 WO2020243273A2 (en) | 2019-05-28 | 2020-05-28 | Methods of treating cholangiocarcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014523A true MX2021014523A (es) | 2022-05-19 |
Family
ID=73552268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014523A MX2021014523A (es) | 2019-05-28 | 2020-05-28 | Metodos para tratar colangiocarcinoma. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220233536A1 (es) |
EP (1) | EP3976042A4 (es) |
JP (1) | JP2022534742A (es) |
KR (1) | KR20220092455A (es) |
CN (1) | CN114144180A (es) |
AU (1) | AU2020284558A1 (es) |
CA (1) | CA3141869A1 (es) |
EA (1) | EA202193276A1 (es) |
IL (1) | IL288353A (es) |
MX (1) | MX2021014523A (es) |
SG (1) | SG11202112902YA (es) |
WO (1) | WO2020243273A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3217517A1 (en) * | 2021-05-19 | 2022-11-24 | Christopher H. Moy | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2898326C (en) * | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
-
2020
- 2020-05-28 CN CN202080053191.1A patent/CN114144180A/zh active Pending
- 2020-05-28 EA EA202193276A patent/EA202193276A1/ru unknown
- 2020-05-28 JP JP2021570792A patent/JP2022534742A/ja active Pending
- 2020-05-28 US US17/613,651 patent/US20220233536A1/en active Pending
- 2020-05-28 SG SG11202112902YA patent/SG11202112902YA/en unknown
- 2020-05-28 AU AU2020284558A patent/AU2020284558A1/en active Pending
- 2020-05-28 CA CA3141869A patent/CA3141869A1/en active Pending
- 2020-05-28 WO PCT/US2020/034881 patent/WO2020243273A2/en unknown
- 2020-05-28 KR KR1020217042644A patent/KR20220092455A/ko unknown
- 2020-05-28 EP EP20813288.6A patent/EP3976042A4/en active Pending
- 2020-05-28 MX MX2021014523A patent/MX2021014523A/es unknown
-
2021
- 2021-11-24 IL IL288353A patent/IL288353A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3976042A4 (en) | 2023-06-28 |
EP3976042A2 (en) | 2022-04-06 |
WO2020243273A9 (en) | 2022-02-10 |
CN114144180A (zh) | 2022-03-04 |
WO2020243273A3 (en) | 2021-01-07 |
US20220233536A1 (en) | 2022-07-28 |
SG11202112902YA (en) | 2021-12-30 |
AU2020284558A1 (en) | 2022-01-06 |
EA202193276A1 (ru) | 2022-03-29 |
JP2022534742A (ja) | 2022-08-03 |
WO2020243273A2 (en) | 2020-12-03 |
KR20220092455A (ko) | 2022-07-01 |
CA3141869A1 (en) | 2020-12-03 |
IL288353A (en) | 2022-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502142A1 (en) | Tetrasubstituted aklene compounds and their use | |
MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
PH12016502354A1 (en) | Pharmaceutical composition | |
MX2021002321A (es) | Nuevos metodos. | |
MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
MX2022000143A (es) | Metodos novedosos. | |
PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
MX2021002322A (es) | Nuevos metodos. | |
MX2020011453A (es) | Combinaciones para tratar el cancer. | |
MX2022007911A (es) | Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7. | |
JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2017002825A (es) | Tratamientos medicos a base de anamorelina. | |
MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
MX2022003945A (es) | Metodo para tratar vih con cabotegravir y rilpivirina. | |
MX2021011529A (es) | Chiauranib para el tratamiento de cáncer de pulmón microcítico. | |
MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
MX2022003628A (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. | |
MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. |